CellaVision AB: Resolutions from Annual General Meeting 2009


The CellaVision Annual General Meeting (AGM) convened earlier today
in Lund, April 27 2009, and resolved as follows:

Statement of Income and Balance Sheet for the parent company and the
Group for the year 2008 was adopted. The AGM approved the Board of
Directors' and CEO's proposal to carry forward the profits at the
disposal of the Meeting of SEK 32,248,603.

The AGM discharged the members of the Board and the Chief Executive
Officer from liability.

The AGM decided that the Board of Directors shall consist of five
regular members and no alternatives. The ordinary Board Members Niels
Freiesleben, Christer Fåhraeus, Lars Gatenbeck, Sven-Åke Henningsson
and Torbjörn Kronander were re-elected and Lars Gatenbeck was elected
Chaiman of the Board.

The AGM decided that the remuneration to the Chairman of the Board
shall amount to SEK 140,000 (140,000). The remuneration to other
directors shall amount to SEK 70,000 (70,000) each, in total to the
Board SEK 420,000 (420,000). Remuneration to the auditors shall be
paid on a current account basis.

The General Annual Meeting's complete decisions as accounted for
above are available at the company address, Ideon Science Park in
Lund, and are sent to those share holders who request it.


Lund April 27, 2009

CellaVision AB (publ)
Board of Directors


CEO Yvonne Mårtensson's address to the meeting is available at
www.cellavision.com.


For more information, please contact:
Lars Gatenbeck, Chairman of the Board, CellaVision AB.
Tel: +46 70 535 44 44. E-mail: lars.gatenbeck@gzgroup.se
Yvonne Mårtensson, CEO, CellaVision AB.
Tel: +46 708 33 77 82. E-mail: yvonne.martensson@cellavision.com


About CellaVision
CellaVision AB develops, markets, and sells market leading image
analysis based systems for routine analysis of blood and other body
fluids. The company has a core competence in development of software
and hardware for automatic image analysis of cells and cell changes
for applications in health and medical care. The company develops and
markets systems for automatic differentials of white blood cells and
red morphology, and software for education and quality assurance of
differentials. The company's associates have expertise in advanced
imaging analysis, artificial intelligence, and automated microscopy.

The company headquarters are in Lund, Sweden. The company also has
subsidiaries in Florida, USA, Toronto, Canada and Yokohama, Japan.
For more information, visit www.cellavision.com.

CellaVision's share is listed on First North Premier at the OMX
Stockholm Stock Exchange. The company's Certified Advisor is Remium
AB.